Literature DB >> 20158689

Parvovirus B19 infection transmitted by transfusion of red blood cells confirmed by molecular analysis of linked donor and recipient samples.

Mei-Ying W Yu1, Harvey J Alter, Maria Luisa A Virata-Theimer, Yansheng Geng, Li Ma, Cathy A Schechterly, Camilla A Colvin, Naomi L C Luban.   

Abstract

BACKGROUND: Extremely high viremic levels of parvovirus B19 (B19V) can be found in acutely infected, but asymptomatic donors. However, reports of transmission by single-donor blood components are rare. In this prospective study, paired donor-recipient samples were used to investigate the transfusion risk. STUDY DESIGN AND METHODS: Posttransfusion plasma or blood samples from recipients were tested for B19V DNA by polymerase chain reaction, generally at 4 and 8 weeks, and for anti-B19V immunoglobulin (Ig)G by enzyme immunoassay, at 12 and 24 weeks. To rule out infection unrelated to transfusion, pretransfusion samples and linked donor's samples for each B19V DNA-positive recipient were assayed for B19V DNA and anti-B19V IgG and IgM. To confirm transmission, sequencing and phylogenetic analysis were performed.
RESULTS: A total of 14 of 869 (1.6%) recipients were B19V DNA positive, but only 1 of 869 (0.12%; 95% confidence interval, 0.0029%-0.6409%) was negative for B19V DNA and anti-B19V IgG before transfusion and seroconverted posttransfusion. This newly infected patient received 5 × 10(10) IU B19V DNA in one red blood cell (RBC) unit from an acutely infected anti-B19V-negative donor in addition to RBCs from three other donors that cumulatively contained 1320 IU of anti-B19V IgG. DNA sequencing and phylogenetic analysis showed that sequences from the linked donor and recipient were identical (Genotype 1), thus establishing transfusion transmission.
CONCLUSIONS: The 0.12% transmission rate documented here, although low, could nonetheless result in hundreds or thousands of infections annually in the United States based on calculated confidence limits. Although most would be asymptomatic, some could have severe clinical outcomes, especially in neonates and those with immunocompromised or hemolytic states.
© 2010 American Association of Blood Banks.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20158689      PMCID: PMC5547753          DOI: 10.1111/j.1537-2995.2010.02591.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  43 in total

Review 1.  The transfusion-associated transmission of parvovirus B19.

Authors:  A Azzi; M Morfini; P M Mannucci
Journal:  Transfus Med Rev       Date:  1999-07

2.  The immune response to parvovirus B19 exposure in previously seronegative and seropositive individuals.

Authors:  Sean Doyle; Amanda Corcoran
Journal:  J Infect Dis       Date:  2006-06-09       Impact factor: 5.226

3.  Report of a collaborative study to establish the international standard for parvovirus B19 serum IgG.

Authors:  M Ferguson; D Walker; B Cohen
Journal:  Biologicals       Date:  1997-09       Impact factor: 1.856

4.  Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization.

Authors:  E Santagostino; P M Mannucci; A Gringeri; A Azzi; M Morfini; R Musso; R Santoro; M Schiavoni
Journal:  Transfusion       Date:  1997-05       Impact factor: 3.157

5.  Persistent parvovirus B19 infection.

Authors:  J R Kerr; M D Curran; J E Moore; P V Coyle; W P Ferguson
Journal:  Lancet       Date:  1995-04-29       Impact factor: 79.321

6.  Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assay.

Authors:  L J Anderson; C Tsou; R A Parker; T L Chorba; H Wulff; P Tattersall; P P Mortimer
Journal:  J Clin Microbiol       Date:  1986-10       Impact factor: 5.948

7.  Parvovirus B19 transmission by heat-treated clotting factor concentrates.

Authors:  Johannes Blümel; Ivo Schmidt; Wolfgang Effenberger; Holger Seitz; Hannelore Willkommen; Hans Herrmann Brackmann; Johannes Löwer; Anna Maria Eis-Hübinger
Journal:  Transfusion       Date:  2002-11       Impact factor: 3.157

8.  Persistent B19 infection in immunocompetent individuals: implications for transfusion safety.

Authors:  Jean-Jacques Lefrère; Annabelle Servant-Delmas; Daniel Candotti; Martine Mariotti; Isabelle Thomas; Yvon Brossard; François Lefrère; Robert Girot; Jean-Pierre Allain; Syria Laperche
Journal:  Blood       Date:  2005-06-23       Impact factor: 22.113

9.  Evaluation of different assays for the detection of parvovirus B19 DNA in human plasma.

Authors:  Sally A Baylis; Nita Shah; Philip D Minor
Journal:  J Virol Methods       Date:  2004-10       Impact factor: 2.014

10.  Neutralization of human parvovirus B19 by plasma and intravenous immunoglobulins.

Authors:  Jens Modrof; Andreas Berting; Björn Tille; Andreas Klotz; Christina Forstner; Sandra Rieger; Claudia Aberham; Matthias Gessner; Thomas R Kreil
Journal:  Transfusion       Date:  2007-09-27       Impact factor: 3.157

View more
  11 in total

1.  Selfness-nonselfness in designing an anti-B19 erythrovirus vaccine.

Authors:  Candida Fasano; Darja Kanduc
Journal:  Self Nonself       Date:  2011-04-01

2.  Characterization of Markers of the Progression of Human Parvovirus B19 Infection in Virus DNA-Positive Plasma Samples.

Authors:  Xavier Bonjoch; Francesc Obispo; Cristina Alemany; Ana Pacha; Esteban Rodríguez; Dolors Xairó
Journal:  Transfus Med Hemother       Date:  2015-04-23       Impact factor: 3.747

3.  Distribution of parvovirus B19 DNA in blood compartments and persistence of virus in blood donors.

Authors:  Tzong-Hae Lee; Steven H Kleinman; Li Wen; Lani Montalvo; Deborah S Todd; David J Wright; Leslie H Tobler; Michael P Busch
Journal:  Transfusion       Date:  2011-02-08       Impact factor: 3.157

4.  Parvovirus B19 Passive Transmission by Transfusion of Intercept® Blood System-Treated Platelet Concentrate.

Authors:  Peter Gowland; Stefano Fontana; Martin Stolz; Nicola Andina; Christoph Niederhauser
Journal:  Transfus Med Hemother       Date:  2016-05-03       Impact factor: 3.747

Review 5.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

6.  Seroepidemiology of parvovirus B19 in the Frankfurt am Main area, Germany: evaluation of risk factors.

Authors:  C Reinheimer; R Allwinn; H W Doerr; M Wittek
Journal:  Infection       Date:  2010-06-17       Impact factor: 7.455

7.  Serological study on parvovirus B19 infection in multitransfused thalassemia major patients and its transmission through donor units.

Authors:  Janak Kishore; Manisha Srivastava; Nabajyoti Choudhury
Journal:  Asian J Transfus Sci       Date:  2011-07

8.  The human parvovirus B19/human immunodeficiency virus co-infection in healthy eligible voluntary blood donors at the Blood Transfusion National Center in Kinshasa.

Authors:  Chabo Byaene Alain; Lufimbo Katawandja Antoine; Bizeti Nsangu Bizette; Pambu Dahlia; Tshibuela Beya Dophie; Muwonga Masidi Jérémie; Kayembe Nzongola-Nkasu Donatien; Ahuka Mundeke Steve
Journal:  Pan Afr Med J       Date:  2020-03-10

9.  Alternative blood products and clinical needs in transfusion medicine.

Authors:  Carolyn Whitsett; Stefania Vaglio; Giuliano Grazzini
Journal:  Stem Cells Int       Date:  2012-04-08       Impact factor: 5.443

Review 10.  Parvovirus B19: What Is the Relevance in Transfusion Medicine?

Authors:  David Juhl; Holger Hennig
Journal:  Front Med (Lausanne)       Date:  2018-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.